MedTrace Logo

Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection

NCT01643785 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-22

No results posted yet for this study

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of the second-line eradication therapy against Helicobacter pylori.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Second-line quadruple therapy with endonase

Compare Second-line quadruple therapy w/o pronase (endonase)

Sponsors & Collaborators

  • Chuncheon Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • JinBong Kim, MD · Chuncheon Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01643785 on ClinicalTrials.gov